SCHEMBL4478445

SCHEMBL4478445

CC(=O)c1c(C)nn2ncccc12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.43
MGLL Q99685 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
KMT2A Q03164 1/20 0.38
PTGS2 P35354 3/20 0.38
CDK4 P11802 1/20 0.38
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 1/20 0.34
EGFR P00533 1/20 0.34
SRC P12931 1/20 0.34
POLB P06746 2/20 0.33
THRB P10828 1/20 0.33
ELANE P08246 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20669578 0.87 DYRK1A (0.43) DYRK1AMGLLKMT2APTGS2CDK4
SCHEMBL4478847 0.80 KDR (0.41) DYRK1AALDH1A1PTGS2CDK4MAPK1
SCHEMBL4480362 0.78 GSK3B (0.43) DYRK1AMGLLALDH1A1KMT2APTGS2
SCHEMBL4471819 0.78 PTGS2 (0.52) HSD17B10KMT2APTGS2POLB
SCHEMBL4471179 0.77 TDP1 (0.44) DYRK1AALDH1A1KMT2APOLBTDP1
SCHEMBL4471173 0.77 TDP1 (0.44) DYRK1AALDH1A1KMT2APOLBTDP1
SCHEMBL4478240 0.75 PTGS2 (0.56) PTGS2
SCHEMBL4480066 0.75 GSK3B (0.44) ALDH1A1KMT2APTGS2
SCHEMBL4471815 0.75 ALDH1A1 (0.39) MGLLALDH1A1KMT2ACDK4POLB
SCHEMBL16329822 0.74 DYRK1A (0.49) DYRK1APTGS2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582630-B2 Pyradazine compounds as GSK-3 inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-01 US disclosed
US-7279473-B2 Pyrazolopyridazine derivatives SMITHKLINE BEECHAM CORPORATION (US) 2007-10-09 US disclosed
EP-1463730-B1 PYRAZOLOPYRIDAZINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20060069097-A1 Pyradazine compounds as gsk-3 inhibitors SMITHKLINE BEECHAM CORPORATION 2006-03-30 US disclosed
EP-1551842-A1 PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-13 EP disclosed
US-20050090507-A1 Pyrazolopyridazine derivatves SMITHKLINE BEECHAM CORPORATION 2005-04-28 US disclosed
EP-1463730-A1 PYRAZOLOPARIDAZINE DERIVATIVES SmithKline Beecham Corporation (US) 2004-10-06 EP disclosed
WO-2004035588-A1 PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed
WO-2003051886-A1 PYRAZOLOPYRIDAZINE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090507-A1 Pyrazolopyridazine derivatves CDK4, CDK3, CDK8 DYRK1A 1097/4885MGLL 4678/4885ALDH1A1 1851/4885
US-20060069097-A1 Pyradazine compounds as gsk-3 inhibitors GSK3B, GSK3A, GSKIP DYRK1A 293/4885MGLL 4501/4885ALDH1A1 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.